Objectives: Sleep staging from polysomnographic (PSG) recordings is clinically critical for diagnosing sleep-related disorders, yet manual scoring by certified technologists remains time-consuming, costly, and subject to inter-rater variability. Methods: This study presents an automated, explainable, and multimodal framework for five-class sleep stage classification using simultaneously acquired electroencephalography (EEG), electrooculography (EOG), and electromyography (EMG) signals. A total of 1946 annotated 30 s epochs from 30 healthy adult recording sessions (Sleep-EDF Expanded and Sleep Cassette subset) were processed through a 37-dimensional multimodal feature extraction pipeline encompassing temporal amplitude statistics, frequency-domain spectral band powers, nonlinear entropy and complexity measures, and Daubechies-4 discrete wavelet transform (DWT) energy coefficients. Four classical machine learning classifiers -Random Forest (RF), Support Vector Machine with radial basis function kernel (SVM-RBF), Gradient Boosting (GB), and K-Nearest Neighbours (KNN, k = 7) were benchmarked under stratified five-fold cross-validation. Results: SVM-RBF achieved the highest macro-averaged F1-score of 0.7322 (Cohen’s kappa 0.6784, overall accuracy 75.18%). N3 deep slow-wave sleep achieved the highest per-class F1 of 0.879, while N1 light sleep was the most challenging (F1 = 0.668). SHapley Additive exPlanations (SHAP) and RF mean decrease in Gini impurity (MDGI) analysis jointly identified EMG root mean square amplitude (MDGI = 0.0805), gamma band power (0.0784), and permutation entropy (0.0434) as the three most discriminative features. As a novel methodological contribution, sixteen categories of signal sculpting visualisations were developed, translating abstract multivariate features into clinically interpretable graphical representations. Conclusions: The proposed framework achieves substantial kappa agreement approaching the lower bound of expert inter-rater reliability (0.76–0.82) while providing full model transparency, with direct implications for wearable sleep monitoring device design.
As the global burden of Alzheimer's disease (AD) continues to grow, early and accurate detection has become increasingly critical, especially in regions with limited access to advanced diagnostic tools. We propose BRAINS (Biomedical Retrieval-Augmented Intelligence for Neurodegeneration Screening) to address this challenge. This novel system harnesses the powerful reasoning capabilities of Large Language Models (LLMs) for Alzheimer's detection and monitoring. BRAINS features a dual-module architecture: a cognitive diagnostic module and a case-retrieval module. The Diagnostic Module utilizes LLMs fine-tuned on cognitive and neuroimaging datasets -- including MMSE, CDR scores, and brain volume metrics -- to perform structured assessments of Alzheimer's risk. Meanwhile, the Case Retrieval Module encodes patient profiles into latent representations and retrieves similar cases from a curated knowledge base. These auxiliary cases are fused with the input profile via a Case Fusion Layer to enhance contextual understanding. The combined representation is then processed with clinical prompts for inference. Evaluations on real-world datasets demonstrate BRAINS effectiveness in classifying disease severity and identifying early signs of cognitive decline. This system not only shows strong potential as an assistive tool for scalable, explainable, and early-stage Alzheimer's disease detection, but also offers hope for future applications in the field.
21 September 2026 in Discover Artificial Intelligence
Diabetic Retinopathy (DR) is one of the major causes of preventable blindness globally. Automated screening for DR is critical but is severely hindered by data scarcity and class imbalance. Real-world datasets, such as APTOS 2019, exhibit extreme class imbalance, where sight-threatening classes are statistically rare. Traditional augmentation fails to capture complex pathological features, while Generative Adversarial Networks (GANs) often suffer from mode collapse. Existing diffusion approaches typically operate in pixel space, limiting image resolution and requiring extreme computational resources. To address this, we introduce the Diabetic Retinopathy Latent Diffusion Synthesizer (DR-LDS), a class-conditional framework that synthesizes high-fidelity, \(512 \times 512\) fundus images natively deployable on consumer-grade hardware. By leveraging a fine-tuned Variational Autoencoder (VAE) for domain-adapted latent space compression, alongside an optimized U-Net, our method achieves superior anatomical realism with convergence in just 150 epochs (at 17 min 22 s per epoch). Extensive benchmarking demonstrates that DR-LDS outperforms state-of-the-art baselines, achieving a Fréchet Inception Distance (FID) of 8.05. When used to augment minority classes to a uniform target for the APTOS 2019 dataset across 11 deep learning architectures, our synthetic data significantly improved diagnostic accuracy by up to 15.25% (\(p < 0.001\)), enabling a lightweight SqueezeNet model to reach 95.60% validation accuracy and an F1 Score of 0.96. Moreover, rigorous data leakage analyses and Explainable AI (XAI) verify that DR-LDS learns genuine pathological biomarkers. This study establishes DR-LDS as a highly resource-efficient solution to the medical data bottleneck. The source code is available at: https://github.com/Touhid-Alam/DR-LDS